CALL/NOVO-NORDISK B/1500/0.1/19.12.25 | Real-time Bid/Ask 03:04:19 12/06/2024 pm IST | ||
| 0.61 EUR / 0.66 EUR | +2.42% |
|
| Current month | +29.17% | ||
| 1 month | +44.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 12/24/12 | 0.6 | -3.23% |
| 11/24/11 | 0.62 | +3.33% |
| 10/24/10 | 0.6 | +3.45% |
| 07/24/07 | 0.58 | -1.69% |
| 06/24/06 | 0.59 | +13.46% |
Delayed Quote Börse Stuttgart
Last update June 12, 2024 at 12:59 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG4UHN |
| ISIN | DE000GG4UHN3 |
| Date issued | 05/03/2024 |
| Strike | 1,500 kr |
| Maturity | 19/12/2025 (556 Days) |
| Parity | 10 : 1 |
| Emission price | 0.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.62 € |
|---|---|
| Lowest since issue | 0.39 € |
| Spread | 0.05 € |
| Spread % | 7.58% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
982
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.35%
- Stock Market
- Warrants
- Warrant
